We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: A High Price for Rare Cancer Drugs
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Medical Ethics > A High Price for Rare Cancer Drugs
BusinessMedical Ethics

A High Price for Rare Cancer Drugs

gooznews
gooznews
Share
5 Min Read
SHARE

Pfizer last week won Food and Drug Administration “accelerated approval” for Xalkori (crizotinib) for a rare form of metastatic lung cancer that strikes about 3 percent of people — almost always non-smokers — who come down with the disease. That’s about 10,000 patients per year in the U.S., and perhaps a similar number abroad. Multiply that times the $$115,200 a year the company plans to charge for Xalkori, and they’ve got themselves a billion dollar blockbuster.

Pfizer last week won Food and Drug Administration “accelerated approval” for Xalkori (crizotinib) for a rare form of metastatic lung cancer that strikes about 3 percent of people — almost always non-smokers — who come down with the disease. That’s about 10,000 patients per year in the U.S., and perhaps a similar number abroad. Multiply that times the $$115,200 a year the company plans to charge for Xalkori, and they’ve got themselves a billion dollar blockbuster.

What does it mean when a drug earns “accelerated approval”? Unfortunately, too many people think this means that it worked so well that the FDA rushed it to market. That’s not how it works. Accelerated approval, which really should be called interim approval, is reserved for drugs that show promise for treating life-threatening diseases like lung cancer, which is the best way to describe Xalkori.

In two single-arm clinical trials (no comparison arm) involving 255 patients, Xalkori delayed tumor progression for about 10 months in slightly more than half the patients who had a specific genetic mutation. Will it prolong survival? That isn’t known yet. Those findings must await the results of follow-up trials, which will contain a placebo arm and will evaluate the drug’s potential for delaying death, not just the surrogate marker of delayed tumor progression, which may or may not signal improved prospects for survival.

More Read

New Technologies at Medtech Startups, October 2011
On Patenting Genes and Their Correlations: It’s a Chicken-Egg Problem
Bone Marrow Donation and Compensation: My Moral Dilemma
Is Your Dentistry Practice Present on Top Social Media Sites?
Rejoinder to yesterday’s Medicare post

How long will it take for Pfizer to complete those trials? At least a couple of years, since that is the life expectancy of most patients diagnosed with metastatic lung cancer whether they have the particular mutation targeted by Xalkori or not. And it might take a lot longer, since the “excitement” among oncologists (see this MedPage Today story) may make it difficult to recruit patients with that mutation to enter a clinical trial where they have a 50-50 chance of getting a placebo. It’s a ready-made excuse for Pfizer, should it fail to complete the trials in a timely manner, which has happened in a large handful of cases involving cancer drugs given accelerated approval.

Through this period where there will be no concrete proof of efficacy, Pfizer will get to charge an outlandishly high price for the drug. Is there a way to put pressure on the company to complete the trials in a more timely fashion, so that the paying public knows that it is truly getting value for its health care dollar and not subjecting patients to some pretty rough side effects (nausea, diarrhea, etc.) for no benefit? Last October, an article appeared in Health Affairs suggesting that Medicare should only pay the asked price for a drug that has not yet proven its superiority to existing treatments for up to a maximum of three years. If the company doesn’t provide clinical proof justifying the higher price within that time, the authors suggested, Medicare should simply pay the rate charged for the best “proven” therapy, which in cancer chemotherapy, is almost always a generic.

A similar model could be applied to drugs given accelerated approval. Medicare and private insurers could agree to pay the asked $115,200 a year for this drug  for three years, which is a reasonable time to complete the final trials. After that, it should be generic pricing until the company comes up with definitive proof.

TAGGED:cancerPfizerpharmaceuticals
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Flat editorial illustration: Healthcare volunteer communication as a two-way, coordinator-supported process for confirming schedu
How to Manage Volunteer Communication in Healthcare: 5 Tactical Steps and Software Options
Global Healthcare
November 18, 2026
The Nervous System Reset Guide: Simple Ways To Manage Stress -- AI-generated illustration
The Nervous System Reset Guide: Simple Ways To Manage Stress
Infographics Mental Health
November 14, 2026
Flat editorial illustration: A single digital quality-management platform connects document control, electronic approval, audit r
6 Best QMS Software Platforms for ISO 13485 and FDA Part 820 (QMSR)
Global Healthcare Policy & Law
November 12, 2026
Flat editorial illustration: Healthcare editorial illustration about accurate patient intake connecting registration, clinical re
The Role of Patient Data Accuracy in Healthcare Operations
Global Healthcare Policy & Law
November 11, 2026

You Might also Like

Drug Company to Congress: The ‘Dog Ate My Homework’

September 9, 2011

The Typical Physician Misses Hundreds of Opportunities to Engage, Empower and Excite Patients Every Day

December 17, 2013
Newsletter_Pic2_07_30_2015
Business

What’s the Right “Level of Care” for Your Marketing?

July 29, 2015
Report Card
Hospital Administration

Leapfrog and the Hospital Safety Score

November 29, 2012
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?